Veracyte | VCYT

Stock Price
32.43
Daily Change
0.91 2.89%
Monthly
35.29%
Yearly
13.51%
Q3 Forecast
32.16

Peers Price Chg Day Year Date
Agilent 128.75 0.27 0.21% -6.04% Sep/05
Arrowhead Research 29.08 1.08 3.86% 30.87% Sep/05
Bruker 30.83 1.04 3.49% -51.84% Sep/05
Exact Sciences 53.81 2.40 4.67% -8.97% Sep/05
Illumina 98.93 1.25 1.28% -20.47% Sep/05
Ligand Pharmaceuticals 166.75 -0.99 -0.59% 64.87% Sep/05
Laboratory Of America 278.67 3.44 1.25% 24.30% Sep/05
Myriad Genetics 6.61 -0.18 -2.65% -75.49% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sonic Healthcare 22.94 -0.07 -0.30% -15.63% Sep/05
Siemens 226.00 -4.05 -1.76% 38.99% Sep/06
Thermo Fisher Scientific 492.60 3.11 0.64% -19.59% Sep/05
Veracyte 32.43 0.91 2.89% 13.51% Sep/05
Waters 306.32 6.63 2.21% -6.72% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Veracyte traded at $32.43 this Friday September 5th, increasing $0.91 or 2.89 percent since the previous trading session. Looking back, over the last four weeks, Veracyte gained 35.29 percent. Over the last 12 months, its price rose by 13.51 percent. Looking ahead, we forecast Veracyte to be priced at 32.16 by the end of this quarter and at 31.37 in one year, according to Trading Economics global macro models projections and analysts expectations.

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.